Compugen Ltd.
(Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a
leader in predictive target discovery, today announced that it will
present updates on its ongoing Phase 1 clinical trial evaluating COM701,
a first-in-class therapeutic antibody targeting PVRIG, for the
treatment of advanced solid tumors in an oral presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I on April 27, 2020 at 11:45 AM EST.
The
presentation, titled, “COM701 demonstrates preliminary antitumor
activity as monotherapy and in combination with nivolumab in patients
with advanced solid tumors”, will include updates from the dose
escalation arms of COM701 monotherapy and in combination with nivolumab.
The presentation will be delivered by Ryan Sullivan, M.D., Assistant Professor, Medicine, Harvard Medical School and Assistant Professor, Hematology/Oncology, Massachusetts General Hospital.
The presentation will be made available on Compugen’s website at www.cgen.com following the conclusion of the presentation.
https://finance.yahoo.com/news/compugen-present-data-com701-phase-110000403.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.